Repligen Co. (NASDAQ:RGEN – Get Free Report) CEO Anthony Hunt purchased 2,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the acquisition, the chief executive officer now directly owns 165,177 shares of […]
Rhenman & Partners Asset Management AB acquired a new stake in Repligen Co. (NASDAQ:RGEN – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $1,798,000. A number of other hedge […]
Westfield Capital Management Co. LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 20.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 294,222 shares of the biotechnology company’s stock after purchasing an additional 49,727 shares during the quarter. Westfield Capital […]
BNP Paribas Asset Management Holding S.A. reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 330,848 shares of the biotechnology company’s stock after selling 14,538 shares during the […]
BNP Paribas Asset Management Holding S.A. trimmed its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 4.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 330,848 shares of the biotechnology company’s stock after selling 14,538 shares during the quarter. BNP Paribas Asset Management Holding S.A.’s holdings in Repligen were worth $59,486,000 as of […]